TY - JOUR
T1 - Expression of bcl-2-, p53, and Ki-67 and outcome of patients with primary nasopharyngeal carcinomas following DNA-damaging treatment
AU - Masuda, Muneyuki
AU - Shinokuma, Atushi
AU - Hirakawa, Naoya
AU - Nakashima, Torahiko
AU - Komiyama, Sohtaro
PY - 1998/10/1
Y1 - 1998/10/1
N2 - Background: Recent studies suggest that apoptosis is important in the cell death induced by treatment that damages deoxyribonucleic acid (DNA). We assessed the correlation between the expression of the apoptosis-related proteins, p53 and bcl-2, and the clinical outcome of patients with nasopharyngeal carcinomas (NPCs) who were treated with both DNA-damaging treatments. We also assessed the level of Ki-67, a marker of cell proliferation, in these tumors. Methods: We evaluated statistically the relationships among the expression of p53, bcl-2, and Ki-67 and clinicopathologic factors, the sensitivity to radiation, the incidence of distant metastases, and survival. Results: The group that was positive for p53 tended to be resistant to radiotherapy and to have a significantly poorer prognosis (p = .05). Conclusions: The enhanced expression of p53 may be a prognostic factor in patients with NPCs whose tumor is resistant to therapy that damages DNA.
AB - Background: Recent studies suggest that apoptosis is important in the cell death induced by treatment that damages deoxyribonucleic acid (DNA). We assessed the correlation between the expression of the apoptosis-related proteins, p53 and bcl-2, and the clinical outcome of patients with nasopharyngeal carcinomas (NPCs) who were treated with both DNA-damaging treatments. We also assessed the level of Ki-67, a marker of cell proliferation, in these tumors. Methods: We evaluated statistically the relationships among the expression of p53, bcl-2, and Ki-67 and clinicopathologic factors, the sensitivity to radiation, the incidence of distant metastases, and survival. Results: The group that was positive for p53 tended to be resistant to radiotherapy and to have a significantly poorer prognosis (p = .05). Conclusions: The enhanced expression of p53 may be a prognostic factor in patients with NPCs whose tumor is resistant to therapy that damages DNA.
UR - http://www.scopus.com/inward/record.url?scp=0031753716&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031753716&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0347(199810)20:7<640::AID-HED11>3.0.CO;2-K
DO - 10.1002/(SICI)1097-0347(199810)20:7<640::AID-HED11>3.0.CO;2-K
M3 - Article
C2 - 9744466
AN - SCOPUS:0031753716
SN - 1043-3074
VL - 20
SP - 640
EP - 644
JO - Head and Neck Surgery
JF - Head and Neck Surgery
IS - 7
ER -